Berberine clinical brief
Berberine
Dossier liveAalkaloid - strongest use in glycemic control
Evidence strength
High confidence
55 meta-analyses - 77 RCTs - 262 tracked studies
What it is for
glycemic control
The clearest current human use case based on dose, outcomes, and clinical coverage.
What moves
Highest-signal biomarkers
Human linked
Fasting glucose
Glycemic control
Decrease
Grade A
HbA1c
Glycemic control
Decrease
Grade A
HOMA-IR
Glycemic control
Decrease
Grade A
Top caution
Metformin
Additive/synergistic glucose-lowering via complementary mechanisms: metformin inhibits hepatic gluconeogenesis (complex I); berberine activates AMPK + inhibits mitochondrial complex I independently.
Evidence index
84
Authored product-registry confidence score
Meta-analyses
55
Pooled human evidence
RCTs
77
Randomized clinical trials
Tracked studies
262
Studies currently mapped to this dossier
Executive summary
Immediate brief
Berberine is a alkaloid sourced from Berberis species with its clearest current use in glycemic control.
High confidence human evidence supports the brief, anchored by 262 tracked studies, 55 meta-analyses, 77 RCTs and the most reliable movement in Fasting glucose, HbA1c, HOMA-IR.
Additive/synergistic glucose-lowering via complementary mechanisms: metformin inhibits hepatic gluconeogenesis (complex I); berberine activates AMPK + inhibits mitochondrial complex I independently. Additive/synergistic glucose-lowering via complementary mechanisms: metformin inhibits hepatic gluconeogenesis (complex I); berberine activates AMPK + inhibits mitochondrial complex I independently.
Anchor decision
glycemic control
Best current human use case
Confidence
High confidence
55 meta-analyses - 77 RCTs - 262 tracked studies
Read next
Metformin
Pressure-test the lead caution before acting.
Reading guide
How to use this brief
1. Orient
Use the overview tab to understand mechanism, safety, scope, and where the current evidence still has blind spots.
2. Pressure-test
Move into evidence and biomarkers once the memo already makes sense, so the tables confirm or challenge the narrative rather than replace it.
3. Operationalize
Finish with dosing and PGx when the compound still looks useful and you are deciding whether it belongs in a real protocol.
Major warning
BPregnancy (all trimesters)
Berberine crosses the placenta; uterotonic activity and embryotoxicity in animal studies; neonatal kernicterus risk via bilirubin displacement from albumin.
Overview
Clinical posture
Start with mechanism and safety, then move into scope, synergies, and the open questions that still matter before going deeper into tables.
Primary signal
Mechanism summary
Read this as the shortest defensible explanation for why the compound belongs in the conversation at all.
Co-primary
Safety summary
These are the reasons this compound can still break trust if the protocol fit is otherwise attractive.
Supporting context
Evidence scope
Read these caveats before assuming the effect sizes generalize cleanly across every population or use case.
Publication bias
ReviewGlycemic evidence (FPG, HbA1c, HOMA-IR) is overwhelmingly derived from Chinese RCTs.
Publication bias
ReviewHao 2022 MA: Egger's test significant for FBG (p<0.05); trim-and-fill adjusted SMD −1.16 vs unadjusted −2.41 - 52% inflation.
Missing populations
CoverageNeeds replication in Sub-Saharan African, South Asian, Middle Eastern, Indigenous/First Nations.
Publication bias
ReviewLipid evidence (LDL-C, TC, TG) similarly concentrated in Chinese populations.
Synergies
Potential pairing logic is useful only when it adds a cleaner decision path, not when it becomes an excuse to stack indiscriminately.
Berberine + Bifidobacterium adolescentis
Berberine+Bifidobacterium (BB, 0.5g BID + 2×10⁸ CFU BID, 16 weeks): HbA1c −0.23% (95%CI −0.38, −0.07) vs placebo (significant); berberine alone: HbA1c −0.06% (NS).
Berberine + Red yeast rice (monacolin K) + CoQ10 + hydroxytyrosol
Body Lipid (berberine 500mg + monacolin K 10mg + CoQ10 2mg + hydroxytyrosol 5mg) once daily for 4 weeks: LDL-C −26.3% (−39.1 mg/dL) vs placebo; TC −45.9 mg/dL; outperformed Armolipid Plus comparator (berberine+monacolin K 3mg: −18.3%).
Berberine + Ursodeoxycholic acid (UDCA)
BUDCA 2000 mg/day (BBR+UDCA ionic salt) for 28 days in Australian hypercholesterolemic non-diabetic adults (n=14 active): TC −8.2% (p=0.0004), LDL-C −10.4% at Day 14 (p=0.0006), non-HDL-C significant at both timepoints.
Research unknowns
These are the open questions that still keep the compound from reading like a closed case.